国内血小板基因库建设及应用的现状研究*

doi:10.3969/j.issn.1671-2587.2024.05.013

临床输血与检验 ›› 2024, Vol. 26 ›› Issue (5): 656-660.DOI: 10.3969/j.issn.1671-2587.2024.05.013

国内血小板基因库建设及应用的现状研究^*

毛伟^1,2, 蒋玉林², 朱传福¹, 叶欣¹, 谢毓滨¹, 李晓丰¹, 吕蓉¹, 齐珺¹, 冯智慧¹, 苏湘辉¹, 徐筠娉¹, 汤龙海¹, 徐晶¹, 谭茜茜¹, 朱发明¹

¹中国输血协会人类组织抗原专业委员会;
²重庆市血液中心,重庆 400052

收稿日期:2024-07-01 出版日期:2024-10-20 发布日期:2024-09-20
通讯作者: 朱发明,主要从事输血医学研究,（E-mail）zfm00@hotmail.com。
作者简介:毛伟,主要从事输血医学研究,（E-mail）275156918@qq.com。
基金资助:
*本课题受重庆市卫生健康委医学科研项目（No.2024WSJK033）、重庆市九龙坡区科技计划项目（No.2023-03-020-Y）、重庆市血液中心科研苗圃计划（No.2023MPJH05）资助

Research on the Establishment and Application of the Genotype Database of Apheresis Platelet Donors in China

MAO Wei^1,2, JIANG Yulin², ZHU Chuanfu¹, YE Xin¹, XIE Yubin¹, LI Xiaofeng¹, LV Rong¹, QI Jun¹, FENG Zhihui¹, SU Xianghui¹, XU Yunping¹, TANG Longhai¹, XU Jing¹, TAN Xixi¹, ZHU Faming¹

¹Working Party on Histocompatibility, Chinese Society of Blood Transfusion (CSBT);
²Chongqing Blood Center Chongqing 400052

Received:2024-07-01 Online:2024-10-20 Published:2024-09-20

摘要/Abstract

摘要： 目的调研国内血小板基因库的建设规模和临床应用情况,了解我国各地区血小板基因库的现状。方法收集来自中国血小板基因数据库协作组的数据和采取自愿上报原则,对2022年度国内27家血站血小板基因库的数据和2021—2023年度14家血站的建库规模、血小板配型数据进行统计分析。结果截止2022年底,全国有27家血站建立血小板HLA基因型资料库,库容量为50~23 940人不等,均值为3 339±5 915人,其中有9家>2 000人;血小板HPA基因型资料库容量为50~7 162人不等,均值为1 636±1 549人,其中有14家>1 000人;全国有27家血站中,13家无CD36阴性献血者,14家有CD36阴性献血者数据,库容量为2~280个,均值为41±73人。2021—2023年全国血小板捐献者HLA和HPA基因型资料库的库容量呈逐年上升的趋势。14家血站2021—2023年的血小板血清学交叉配型数量在20~8 000不等,但血小板基因配合性输注占比差异较大,0%~40%不等,均值<10%。结论国内血小板基因库的规模及应用占比差异大,迫切需要通过扩大血小板捐献者基因型资料库规模、提高血小板基因库的临床使用率,实现血小板的精准输注,进一步保障临床输血的科学性、有效性和安全性。

关键词: 血小板基因库, 建设, 库容量, 应用

Abstract: Objective To understand the current situation of the genotype database of apheresis platelet donors in China by investigating the size of the genotype database of apheresis platelet donors and the application of gene matching transfusion. Methods The data were collected from the platelet gene database collaboration group by the principle of voluntary reporting, and the data of the genotype database of apheresis platelet donors of 27 blood stations in China in 2022, the data of database establishment and platelet cross-matching in 14 blood stations from 2021—2023 were analyzed. Results By the end of 2022, 27 blood stations in China had established platelet HLA genotype databases, with the database capacity ranging from 50 to 23 940, with an average of 3 339±5 915, of which 9 were more than 2 000. The database capacity of platelet HPA genotypes ranged from 50 to 7 162, with an average of 1 636±1549, of which 14 were greater than 1 000. Of the 27 blood stations in China, 13 have no CD36 negative blood donors, and 14 have the data of CD36 negative blood donors, with a capacity of 2-280, with an average of 41±73. From 2021 to 2023, the database capacity of HLA and HPA genotypes of platelet donors in China is increasing year by year. The number of platelet cross-matching in 14 blood stations from 2021 to 2023 ranged from 20 to 8 000, but the proportion of gene matching transfusion varied greatly, ranging from 0% to 40%, with an average of less than 10%. Conclusion There are great differences in the size and application of the genotype database of apheresis platelet donors in China. It is urgent to expand the size and improve the utilization rate of the database to realize accurate platelet transfusion and further ensure the scientific validity, effectiveness and safety of clinical blood transfusion.

Key words: Genotype database of platelet donors, Establishment, Capacity, Application

中图分类号:

R457

毛伟, 蒋玉林, 朱传福, 叶欣, 谢毓滨, 李晓丰, 吕蓉, 齐珺, 冯智慧, 苏湘辉, 徐筠娉, 汤龙海, 徐晶, 谭茜茜, 朱发明. 国内血小板基因库建设及应用的现状研究^*[J]. 临床输血与检验, 2024, 26(5): 656-660.

MAO Wei, JIANG Yulin, ZHU Chuanfu, YE Xin, XIE Yubin, LI Xiaofeng, LV Rong, QI Jun, FENG Zhihui, SU Xianghui, XU Yunping, TANG Longhai, XU Jing, TAN Xixi, ZHU Faming. Research on the Establishment and Application of the Genotype Database of Apheresis Platelet Donors in China[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(5): 656-660.

参考文献

[1] CURTIS B R,MCFARLAND J G.Human platelet antigens - 2013[J]. Vox Sang,2014,106(2):93-102.
[2] STANWORTH S J,NAVARRETE C,ESTCOURT L,et al.Platelet refractoriness—practical approaches and ongoing dilemmas in patient management[J]. Br J Haematol, 2015,171(3):297-305.
[3] WU G G,ZHOU Y,LI L L,et al.Platelet immunology in China:research and clinical applications[J]. Transfus Med Rev,2017,31(2):118-125.
[4] XU X G,LIU Y,HONG X Z,et al.Variants of CD36 gene and their association with CD36 protein expression in platelets[J]. Trasfusione Del Sangue, 2014,12(4):557-564.
[5] LI R S,QIAO Z L,LING B,et al.Incidence and molecular basis of CD36 deficiency in Shanghai population[J]. Transfusion,2015,55(3):666-673.
[6] XU X Z,YE X,XIA W J,et al.Studies on CD36 deficiency in South China:Two cases demonstrating the clinical impact of anti-CD36 antibodies[J]. Thromb Haemost, 2013,110(6):1199-1206.
[7] 朱发明,毛伟,张志欣. 血小板捐献者血型资料数据库的建设与应用展望[J]. 中国输血杂志,2019,32(5):413-416.
[8] 苏蔓,李茵,赵倩,等. 石家庄地区已知HLA型别单采血小板捐献者基因资料库库容评价[J]. 临床输血与检验, 2020,22(3):290-294.
[9] 齐珺,李昱辉,王天菊,等. 陕西地区血小板HLA/HPA基因供者库的建库评估及应用策略[J]. 中国输血杂志,2022, 35(8):799-804.
[10] 赵娜娜,王超,庞霄,等. 合肥地区HPA、HLA高分辨基因型血小板供者库的建立及库容分析[J]. 中国输血杂志, 2022,35(11):1109-1112.
[11] 齐珺,曹晓莉,胡欣,等. 陕西地区血小板供者基因数据库拓展性应用的研究[J]. 中国输血杂志,2023,36(7):637-641.
[12] 张德梅,李卿,徐熠,等. 太原地区血小板库供者特征及应用评价[J]. 中国输血杂志,2022,35(9):970-973.
[13] 魏亚明,桂嵘,王秋实,等. 血小板抗体检测专家共识[J]. 临床输血与检验,2020,22(1):1-5.
[14] 傅启华,王静. 紧急抢救时ABO血型不相同血小板输注专家共识[J]. 中国输血杂志,2017,30(7):666-667.
[15] YıLDıZ A,DOĞAN M,YALVAÇ M,et al. Platelet inventory and using out-of-group platelet suspension:a cost-effective strategy for a blood transfusion service[J]. Hematol Oncol Stem Cell Ther,2023,16(4):337-341.
[16] PANDEY P,KUMARI S,MANDAL S,et al.A prospective observational study to compare transfusion outcomes in ABO identical versus ABO non-identical single donor platelet concentrates:an experience from a tertiary healthcare center in India[J]. Transfus Clin Biol,2022, 29(3):213-218.
[17] 阳雪新,袁咏梅,吴兆勇,等. ABO次侧不相合血小板输注的有效性和安全性初步研究[J]. 临床输血与检验,2024, 26(1):42-49.
[18] SHEHATA N,TINMOUTH A,NAGLIE G,et al.ABO-identical versus nonidentical platelet transfusion: a systematic review[J]. Transfusion,2009,49(11): 2442-2453.
[19] SLICHTER S J,DAVIS K,ENRIGHT H,et al.Factors affecting posttransfusion platelet increments,platelet refractoriness,and platelet transfusion intervals in thrombocytopenic patients[J]. Blood,2005,105(10): 4106-4114.
[20] KREUGER A L,MÄKELBURG A B U,SOMERS J A E, et al. HLA-matched platelet transfusions are effective only in refractory patients with positive HLA antibody screening[J]. Transfusion,2019,59(11):3303-3307.

国内血小板基因库建设及应用的现状研究^*

Research on the Establishment and Application of the Genotype Database of Apheresis Platelet Donors in China

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	陈虹, 张智, 项征国. 基于感性工学的献血场所设计建设实践与探索——以武汉为例[J]. 临床输血与检验, 2024, 26(4): 544-548.
[2]	王国美, 杨佶军, 刘铁梅. 胎母输血综合征检测方法与相关疾病的研究进展^*[J]. 临床输血与检验, 2024, 26(3): 426-432.
[3]	尹明秀, 欧国进, 陈剑, 凤婧, 赵虹. 改良56℃热放散法与冷冻复融放散法对ABO型新生儿溶血病的临床应用价值比较^*[J]. 临床输血与检验, 2024, 26(1): 60-65.
[4]	罗婧菱, 杨磊. 机采血小板成分输注对肝癌细胞增殖转移的影响^*[J]. 临床输血与检验, 2023, 25(4): 456-460.
[5]	黄霞, 杨俊鸿, 何涛. 血液安全监测选择与未来^*[J]. 临床输血与检验, 2023, 25(1): 10-15.
[6]	高明, 魏晴. 人凝血酶原复合物的临床应用新进展[J]. 临床输血与检验, 2022, 24(5): 658-668.
[7]	中国人体健康科技促进会妇科内分泌和生育力促进分会, 中国女医师协会输血专业委员会. 自体富血小板纤维蛋白（PRF）治疗宫腔粘连专家共识[J]. 临床输血与检验, 2022, 24(3): 279-284.
[8]	汪晓晓, 郭建荣. 自体输血在老年患者手术中的应用价值及风险分析^*[J]. 临床输血与检验, 2021, 23(2): 259-262.
[9]	刘爱玲, 刘爱胜, 罗小芳, 吴敏. 肠道轮状病毒巢式PCR检测方法的建立及初步应用^*[J]. 临床输血与检验, 2019, 21(6): 604-607.
[10]	安丽颖, 王鹏, 冯瑞刚, 李小静, 卜烨, 张晨洁, 李凯敏. 21个基因检测评分在乳腺癌复发中的应用效果及影响因素研究^*[J]. 临床输血与检验, 2019, 21(6): 626-629.
[11]	褚宗棠, 王瑛, 赵莲, 周虹. 血红蛋白氧亲和力在临床应用的研究进展^*[J]. 临床输血与检验, 2019, 21(2): 124-129.
[12]	张如, 朱建华, 李强. HCV RNA检测在丙型肝炎诊断中的应用价值[J]. 临床输血与检验, 2019, 21(2): 200-202.
[13]	邵俊良, 徐晓敏, 孙玲玲. 追踪方法学运用于临床输血质量评价中的价值分析[J]. 临床输血与检验, 2018, 20(6): 588-591.
[14]	陈立,李忠俊. 如何构建我国治疗性血浆置换术的教学体系*[J]. 临床输血与检验, 2018, 20(3): 228-230.
[15]	李文华,袁高洁,叶银,滕本秀,李忠俊,冉茜. 血浆置换床旁救治方案的建立及临床应用*[J]. 临床输血与检验, 2018, 20(3): 231-234.